Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07446491) titled 'A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure' on Feb. 26.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
Primary Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd.
Condition:
Thrombocytopenia Associated With Chronic Liver Disease
Intervention:
Drug: PN20
Recruitment Status: Recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: June 6, 2025
Targ...